The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are continuing to investigate multiple instances of Wallcur simulated saline solution being administered to patients. To date, the agencies are aware of more than 40 patients who have received infusions of the simulated saline products. Some of the patients experienced adverse events associated with these products including fever, chills, tremors and headache.
The FDA and the CDC have taken a number of steps to remove the simulated saline products from medical settings, to raise awareness among healthcare providers, and to provide information to state and local health officials in order to prevent exposure to additional patients.
The FDA has been working closely with Wallcur to make several changes to their labeling and marketing practices to prevent this from occurring again. Wallcur has voluntarily:
- Recalled all Practi-0.9% sodium chloride IV bags supplied in 50 mL, 100 mL, 250 mL, 500 mL, and 1000 mL sizes
- Notified all customers and distributors who received recalled products
- Added stickers to existing packaging and labeling of Practi-0.9% sodium chloride IV bags to explicitly warn users that the simulated products are not intended for human or animal use and are for training purposes only
- Continued discussions with FDA concerning labeling recommendations for all simulation products
The FDA is reiterating its previous recommendations that ask health care professionals and consumers to do the following:
- Be vigilant and report any suspected adverse events following use of these products to FDA’s MedWatch program online or at 1-800-332-1088
- Visually inspect all current IV saline solution bags. Ensure none of the bags are labeled “Wallcur,” “Practi-0.9% saline,” or “For clinical training purposes only”
- Consider reviewing clinic procedures and make sure there are procedures in place to visually inspect all future shipments of IV products to ensure they are appropriate for clinical use
View the full FDA update at: http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm.
Source: FDA and CDC
Weekly Rounds: Four Years of COVID-19, AORN 2024 Conference Coverage, and More
March 18th 2024Here are 5 highlights from Infection Control Today®'s (ICT®’s) wide-ranging coverage of the infection prevention and control world. Everything from interviews with known opinion leaders to the news that infection preventionists and other health care professionals can use on their jobs.
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
Could Empathy Help Overcome Vaccine Hesitancy?
March 14th 2024Research findings reveal that correcting misinformation about vaccination can remarkably transform individuals' attitudes toward it. This highlights the crucial role of accurate information in making informed decisions about vaccination.
Empowering Safety: A Massachusetts General Hospital Team Is Pushing for Smoke-Free ORs
March 13th 2024At the AORN’s International Surgical Conference & Expo 2024, a team from Massachusetts General Hospital (MGH) showcased their transformative project, "Becoming Smoke-Free in the OR." This initiative underscored the critical need for smoke evacuation in surgical settings.
Hand Hygiene Practices in the Operating Room: A Collaborative Endeavor
March 13th 2024As explained on a poster at AORN 2024, perioperative nurses and infection preventionists unite in a proactive campaign to elevate hand hygiene within the operating room, resulting in improved adherence, decreased infections, and fortified patient outcomes.